您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > EG01377 dihydrochloride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
EG01377 dihydrochloride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
EG01377 dihydrochloride图片
规格:98%
分子量:659.6
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
100mg电议

产品介绍
EG01377dihydrochloride是有效的、可生物利用的和选择性的neuropilin-1(NRP1)抑制剂,Kd值为1.32μM,对NRP1-a1和NRP1-b1的IC50值均为609nM。EG01377dihydrochloride具有抗血管生成,抗迁移及抗肿瘤等活性。
货号:ajcx29310
CAS:N/A
分子式:C26H32Cl2N6O6S2
分子量:659.6
溶解度:DMSO: 200 mg/mL (303.21 mM)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects[1].

EG01377 (3-30 μM; 30 minutes) inhibits vascular endothelial growth factor A (VEGF-A) stimulated tyrosine phosphorylation of VEGF-R2/KDR[1].EG01377 (30 μM) is able to significantly reduce HUVEC cell migration in response to VEGFA[1].EG01377 (30 μM; 5 days) can delay the VEGF-induced wound closure[1].EG01377 (30 μM) reduces network area, length, and branching points[1].EG01377 (30 μM; 7 days) reduces VEGF-induced angiogenesis[1].EG01377 (30 μM; 7 days) in combination with VEGFA reduces A375P (malignant melanoma) spheroid outgrowth[1].EG01377 (500 nM; 2 hours) blocks the production of transforming growth factor beta (TGFβ) by Nrp1+ regulatory T-cell SMAD3/AKT (Tregs) in the presence of tumor cell-derived factors[1]. Western Blot Analysis[1] Cell Line: Human umbilical vein endothelial cells (HUVECs)

EG01377 (2 mg/kg; i.v.) exhibits an encouraging half-life of 4.29 h, sufficient to sustain once per day dosing in mice[1]. Animal Model: 6-8 week-old BABL/c female mice[1]

[1]. Powell J, et al. Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFβ) Production in Regulatory T-Cells. J Med Chem. 2018 May 10;61(9):4135-4154.